Company / Capital Returned to Shareholders
Vertex Pharmaceuticals Capital Returned to Shareholders History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$2.0B
FY2025
5-year range
$0 / $2.0B
FY2021-FY2025
Trend
+71.4%
vs FY2024
Sector context
#9 of 52
Health Care
What the data says
Vertex Pharmaceuticals's capital returned to shareholders of $2.0B is higher than 83% of companies in the Health Care sector (FY2025). Capital Returned to Shareholders has increased for 3 consecutive years, from $0 in FY2022 to $2.0B in FY2025.
Based on SEC 10-K filings.
$2.0B in FY2025 with a 5-year CAGR of +30.2%. Top quartile in the Health Care sector.
Improved from $428M to $2.0B over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +30.2%
- 10-Year CAGR
- -
Sector benchmark
+51.2% above sector average
Key checks
Key Insights
- 5-year CAGR of +30.2%, indicating consistent growth.
- In FY2025, capital returned to shareholders increased 71.4% year-over-year.
- Ranks #9 out of 52 companies in the Health Care sector.
- Lowest capital returned to shareholders in the period was in FY2022.
Company context
Key Data Points
- Strong profit margin: 31.4%
- Strong return on equity: 21.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.0B | +71.4% |
| FY2024 | $1.2B | +175.3% |
| FY2023 | $427.6M | - |
| FY2022 | $0 | -100.0% |
| FY2021 | $1.4B | +164.4% |
| FY2020 | $539.1M | +189.8% |
| FY2019 | $186.0M | -46.9% |
| FY2018 | $350.0M | - |
| FY2017 | $0 | - |
| FY2016 | $0 | - |
As of FY2025 · SEC 10-K · Updated Mar 17, 2026